B
CRBU icon

Bailard’s Caribou Biosciences CRBU Stock Holding History

Bailard’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,216
Closed -$89.3K – 733
2022
Q4 		$89.3K Sell
14,216
-5,484
-28% -$48.8K ﹤0.01% 686
2022
Q3 		$208K Sell
19,700
-3,800
-16% -$35.4K 0.01% 589
2022
Q2 		$128K Buy
+23,500
New +$180K 0.01% 643
2021
Q4 		– Sell
-8,800
Closed -$210K – 734
2021
Q3 		$210K Buy
+8,800
New +$215K 0.01% 664

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bailard's CRBU Position: Q1 2023 in Review

Bailard sold out of Caribou Biosciences (CRBU) in Q1 2023, closing a stake of 14,216 shares — an estimated $89.3K sold.

Bailard first reported a position in CRBU in Q3 2021 and held it in 4 quarters. The position peaked at $210K in Q3 2021. 126 funds tracked by Wall St. Rank hold CRBU as of Q1 2023.

  • Bailard reported no remaining Caribou Biosciences position as of Q1 2023 after selling out during the quarter.
  • Bailard sold 14,216 Caribou Biosciences shares in Q1 2023, an estimated $89.3K.
  • Bailard first reported a position in Caribou Biosciences in Q3 2021 and held it in 4 quarters.
  • Bailard's Caribou Biosciences position peaked at $210K in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.